Indivior (NASDAQ:INDV) Coverage Initiated by Analysts at Craig Hallum

Research analysts at Craig Hallum assumed coverage on shares of Indivior (NASDAQ:INDVGet Free Report) in a research report issued to clients and investors on Wednesday, reports. The firm set a “buy” rating and a $37.00 price target on the stock. Craig Hallum’s target price would suggest a potential upside of 77.54% from the company’s previous close.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $20.84 on Wednesday. The business’s fifty day moving average price is $19.78 and its two-hundred day moving average price is $18.50. The stock has a market cap of $2.87 billion, a PE ratio of -1,041.48 and a beta of 0.46. Indivior has a one year low of $14.38 and a one year high of $26.50.

Indivior (NASDAQ:INDVGet Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.15. Indivior had a return on equity of 538.18% and a net margin of 0.18%. The company had revenue of $293.00 million for the quarter, compared to analyst estimates of $260.00 million. As a group, equities research analysts predict that Indivior will post 2.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Scopia Capital Management LP purchased a new position in shares of Indivior in the 3rd quarter worth $191,743,000. Goldman Sachs Group Inc. purchased a new position in shares of Indivior in the 2nd quarter worth $83,678,000. Barclays PLC raised its position in shares of Indivior by 746.6% in the 4th quarter. Barclays PLC now owns 3,093,161 shares of the company’s stock worth $47,232,000 after buying an additional 2,727,791 shares during the period. Norges Bank acquired a new stake in Indivior in the 4th quarter valued at $36,011,000. Finally, Liontrust Investment Partners LLP acquired a new stake in Indivior in the 3rd quarter valued at $43,340,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

Recommended Stories

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with's FREE daily email newsletter.